Humoral immune response against P2β from Trypanosoma cruzi in persons with chronic chagas disease: Its relationship with treatment against parasites and myocardial damage

American Journal of Tropical Medicine and Hygiene

Volumn 84, Issue 4, 2011, Pages 575-580

  Fabbro, Diana L ^a   Olivera, Verónica ^a   Bizai, Maria Laura ^a   Denner, Susana ^a   Diez, Cristina ^a   Mancipar, Iván ^a   Streiger, Mirtha ^a   Arias, Enrique ^a   Del Barco, Mónica ^a   Mendicino, Diego ^a   Bottasso, Oscar ^b  

^a UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; COMPLEMENTARY DNA; NIFURTIMOX; PROTEIN ANTIBODY; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN; RIBOSOMAL PROTEIN ANTIBODY; RIBOSOMAL PROTEIN P 2BETA; RIBOSOME PROTEIN; UNCLASSIFIED DRUG; ANTITRYPANOSOMAL AGENT; L12E PROTEIN, TRYPANOSOMA CRUZI; NITROIMIDAZOLE DERIVATIVE;

ADULT; AGGLUTINATION TEST; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CARDIOMYOPATHY; CHAGAS DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG DOSE INCREASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMAGGLUTINATION TEST; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RETROSPECTIVE STUDY; TREATMENT DURATION; TRYPANOSOMA CRUZI; XENODIAGNOSIS; ANIMAL; HUMORAL IMMUNITY; IMMUNOLOGY;

TRYPANOSOMA CRUZI;

ANIMALS; ANTIBODIES, PROTOZOAN; CARDIOMYOPATHIES; CHAGAS DISEASE; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNITY, HUMORAL; MALE; NIFURTIMOX; NITROIMIDAZOLES; PROTOZOAN PROTEINS; RIBOSOMAL PROTEINS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 79958020042     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2011.10-0261     Document Type: Article

References (34)

1. Pan American Health Organization-World Health Organization, 2006. Estimación Cuantitativa de la Enfermedad de Chagas en las Américas. Washington, DC and Geneva: Pan American Health Organization-World Health Organization, OPS/HDM/CD/425-0G.
2. Andrade ZA, 1999. Immunopathology of Chagas disease. Mem Inst Oswaldo Cruz 94: 71-80. (Pubitemid 129584475)
3. Prata A, 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1: 92-100. (Pubitemid 33586044)
4. Reis MM, Higuchi ML, Benvenuti LA, Aiello VD, Gutierrez PS, Bellotti G, Pileggi F, 1997. An in situ quantitative immunohistochemical study of cytokines and IL-2R+ in chronic human chagasic myocarditis: correlation with the presence of myocardial Trypanosoma cruzi antigens. Clin Immunol Immunopathol 83: 165-172. (Pubitemid 27195936)
5. Tarleton RL, 2001. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 31: 550-554. (Pubitemid 32382054)
6. Brener Z, Gazzinelli RT, 1997. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int Arch Allergy Immunol 114: 103-110. (Pubitemid 27397063)
7. Higuchi ML, De Morais F, Pereira-Barreto AC, Lopes EA, Stolf N, Bellotti G, Pileggi F, 1987. The role of active myocarditis in the development of heart failure in chronic Chagas disease: a study based on endomyocardial biopsies. Clin Cardiol 10: 665-670. (Pubitemid 18012754)
8. Pontes-De-Carvalho L, Santana CC, Soares MB, Oliveira GG, Cunha-Neto E, Ribeiro-Dos-Santos R, 2002. Experimental chronic Chagas' disease myocarditis is an autoimmune disease preventable by induction of immunological tolerance to myocardial antigens. J Autoimmun 18: 131-138. (Pubitemid 36268629)
9. Higuchi ML, Brito T, Reis M, Bellotti G, Pereira-Barreto AC, Pileggi F, 1993. Correlation between Trypanosoma cruzi parasitism and myocardial inflammation in human chronic chagasic myocardits. Light microscopy and immunohistochemical findings. Cardiovasc Pathol 2: 101-106.
10. Higuchi ML, Reis M, Aiello VD, Benvenutti LA, Gutierrez PS, Bellotti G, Pileggi F, 1997. Human chronic chagasic myocarditis is Trypanosoma cruzi antigen and CD8+ T cell dependent. Am J Trop Med Hyg 56: 485-489.
11. Jones EM, Colley DG, Tostes S, Lopes ER, Venencak-Jones C, Mc Curley TL, 1993. Amplification of Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. Am J Trop Med Hyg 48: 348-357. (Pubitemid 23115319)
12. Añez N, Carrasco H, Parada H, Crisante G, Rojas A, Fuenmayor C, Gonzalez N, Percoco G, Borges R, Guevara P, Ramírez JL, 1999. Myocardial parasite persistence in chronic chagasic patients. Am J Trop Med Hyg 60: 726-732. (Pubitemid 29233071)
13. Aznar C, Lopez-Bergami P, Brandariz S, Mariette C, Liegeard P, Alves M, Barreiro E, Carrasco R, Lafon S, Kaplan D, Miguez H, Camacho C, Levitus G, Levin M, Hontebeyrie M, 1995. Prevalence of anti- R-13 antibodies in human Trypanosoma cruzi infection. FEMS Immunol Med Microbiol 12: 231-238. (Pubitemid 3007582)
14. Levitus G, Hontebeyre-Joskowicz M, Van Regenmortel M, Levin MJ, 1991. Humoral autoimmune response to ribosomal P proteins in chronic Chagas' heart disease. Clin Exp Immunol 85: 413-417.
15. Lopez Bergami P, Scaglione J, Levin MJ, 2001. Antibodies against the carboxylterminal end of the Trypanosoma cruzi ribosomal P proteins are pathogenic. FASEB J 15: 2602-2612. (Pubitemid 33131087)
16. Masuda MO, Levin M, De Oliveira SF, Dos Santos Costa PC, Bergami PL, Dos Santos Almeida NA, Pedrosa RC, Ferrari I, Hoebeke J, Campos de Carvalho AC, 1998. Functionally active cardiac antibodies in chronic Chagas' disease are specifically blocked by Trypanosoma cruzi antigens. FASEB J 12: 1551-1558. (Pubitemid 28506724)
17. Laucella SA, Pérez Mazliah D, Bertocchi G, Alvarez MG, Cooley G, Viotti R, Albareda MC, Lococo B, Postan M, Armenti A, Tarleton RL, 2009. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 49: 1675-1684.
18. Diez C, Gea S, Marcipar I, Pezzotto S, Beloscar J, Pellizzon O, Marcipar A, Bottasso O, 2006. Cardiovascular risk factors in chronic Chagas' disease are associated with a different profile of putative heart-pathogenic antibodies. FEMS Immunol Med Microbiol 48: 26-33. (Pubitemid 44379217)
19. Sgammini HO, 1981. Criterio de clasificación de la miocardiopatía chagásica. Rev Fed Arg Cardiol 10: 145-152.
20. Marcipar I, Olivares ML, Robles L, Dekanty A, Marcipar A, Silber A, 2004. The diagnostic performance of recombinant Trypanosoma cruzi ribosomal P2 protein is influenced by its expression system. Protein Expr Purif 34: 1-7. (Pubitemid 38272308)
21. Laemmli UK, 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
22. Bradford MM, 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
23. Viotti RJ, Vigliano C, Armenti A, Segura EL, 1994. Treatment of chronic Chagas'disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127: 151-161.
24. Cançado JR, 2002. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 44: 1-21.
25. Viotti RJ, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A, 2006. Long-term cardiac outcomes of treatment chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144: 724-734. (Pubitemid 46780632)
26. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco ML, Amicone NA, 2007. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 40: 1-10. (Pubitemid 46759236)
27. Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodriguez MM, Campos-de-Carvalho AC, Ribeiro-Dos-Santos R, Soares MB, 2005. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 49: 1521-1528. (Pubitemid 40463384)
28. Hyland KV, Leon JS, Daniels MD, Giafis N, Woods LM, Bahk TJ, Wang K, Engman DM, 2007. Modulation of autoimmunity by treatment of an infectious disease. Infect Immun 75: 3641-3650. (Pubitemid 47040967)
29. Levin MJ, Mesri W, Benarous R, Levitus G, Schijman A, Levy-Yeyati P, Chiale PA, Ruiz AM, 1989. Identification of major Trypanosoma cruzi antigenic determinants in chronic Chagas' heart disease. Am J Trop Med Hyg 41: 530-538. (Pubitemid 20000624)
30. Milei J, 1994. Patogenia. Storino R, Milei J, eds. Enfermedad de Chagas. Buenos Aires: Mosby-Doyma, 103-128.
31. Bonney KM, Engman DM, 2008. Chagas heart disease pathogenesis: one mechanism or many? Curr Mol Med 8: 510-518.
32. Kierszenbaum F, 2007. Mechanism of pathogenesis in Chagas disease. Acta Parasitol 52: 1-12.
33. Tarleton RL, 2003. Chagas disease: a role for autoimmunity? Trends Parasitol 19: 447-451.
34. Schwartz D, Lellouch J, 1967. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 20: 637-648.